

July 11, 2025

**To**

BSE Limited  
Corporate Relationship Department  
25th Floor, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001  
**BSE Scrip Code: 524743**

**To**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5th floor Plot No. C/ 1, G  
Block, Bandra-Kurla Complex Bandra (E),  
Mumbai - 400 051  
**NSE Scrip Code: FISCHER**

Dear Sir,

**Reg : Fischer Medical Ventures' JV Partner NYB.AI Clinches Top Global AI Innovation Award**

We enclose a press release regarding **"the SuperAI Genesis competition win by Fischer Medical Ventures Ltd's joint venture partner, Nanyang Biologics (NYB.AI),"** for dissemination.

Thanking you,  
Yours Truly,  
For **FISCHER MEDICAL VENTURES LIMITED**  
(Formerly known as Fischer Chemic Limited)



**ARAVINDKUMAR V**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**



## **Fischer Medical Ventures Ltd Joint Venture Partner, Nanyang Biologics (NYB.AI) Won Top Prize at the SuperAI Genesis Competition for Breakthrough in AI-Powered Drug Discovery**

Chennai, July 11 2025 — *Nanyang Biologics (NYB.AI)* was awarded 1st Prize at the prestigious SuperAI Genesis Startup Competition, selected from a pool of over 700 startups spanning more than 100 countries.

The SuperAI Genesis competition, known for spotlighting the most promising AI-driven ventures globally, saw participation from innovators across **North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East** in its inaugural edition. NYB.AI's groundbreaking approach to AI-driven drug discovery, especially its focus on nature-derived compounds and strong regional applicability captivated judges and audiences alike.

Fischer Medical Ventures Ltd (formerly Fischer Chemic Ltd), a pioneering force in the healthcare industry known for its affordable and accessible medical imaging technologies, cutting-edge innovations, and AI-powered software solutions, is a strategic joint-venture partner of NYB.AI and support the development of their transformative nutraceuticals derived from natural plants and herbs, with the goal of revolutionizing healthcare through innovative, evidence-based products.

### **A Transformative Approach to Drug Discovery**

NYB.AI impressed the judging panel of SuperAI Genesis with its proprietary **DTIGN platform (Drug-Target Interaction Graph Neural Network)**. By combining **graph neural networks** with **molecular docking**, the platform predicts drug-target interactions with high precision, especially in compounds sourced from **Southeast Asia's rich biodiversity**—an area traditionally underexplored by Western pharma.

#### **Key Advantages of NYB.AI's Platform:**

- **25% higher accuracy** compared to the next-best method (as recognized by *IEEE Magazine*)
- **10× faster model training**, reducing computation time from 80 to 10 hours
- **8× faster molecular docking**, with time cut from 70 to 8 hours
- **~64× improvement in hit-rate efficiency** and a **44.8% increase in bioactivity prediction accuracy**

These advantages translate into **accelerated drug development timelines, significant cost savings, and greater success rates** — a game-changer for biotech R&D.

### **Commercial Momentum and Industry Partnerships**

NYB.AI's rapid rise is also supported by major industry partners, including **NVIDIA, Johnson & Johnson Innovation – JLABS, Equinix and Hewlett Packard Enterprise (HPE)**. The company has been selected to present at **NVIDIA's GTC 2025**, further validating its technology's impact and scalability.



### **Visionary Leadership with Global Impact**

Founded by scientists from **Nanyang Technological University (NTU)** with real-world experience in pharmaceutical R&D, NYB.AI combines deep domain knowledge with a forward-thinking vision. Beyond pharmaceuticals, the company's platform has applications in **nutraceuticals, beauty, and animal health**.

### **Judges' Verdict: Innovation, Market Potential, and Scalability**

The SuperAI Genesis judges praised NYB.AI for excelling across all key evaluation metrics:

- **Innovation:** Unique application of GNNs to natural compound discovery
- **Market Potential:** Strong applicability across drug pipelines, supplements, and wellness
- **Scalability:** Proven partnerships and robust AI infrastructure.



**Mr. Ravindran Govindan, Executive Chairman & MD of Fischer Medical Ventures Ltd,** celebrates the win: *"We are honoured to be recognized at SuperAI Genesis. This award reflects the two companies' commitment to unlock the molecular secrets of Indian and Southeast Asian herbs, bringing them to global markets faster and more affordably. We believe there are untapped treasures in Indian traditional medicine, and NYB.AI is here to translate that heritage into modern therapeutics and wellness solutions. We have already at this point uncovered an Indian traditional herb which can help treatment of mental health - a great breakthrough!"*

For further information, please contact:

**Fischer Medical Ventures Limited**

Email: [enquiry@fischermv.com](mailto:enquiry@fischermv.com)

Website: [www.fischermv.com](http://www.fischermv.com)

Contact: **9080966548**



**Disclaimer:**

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (formerly known as Fischer Chemic Ltd) (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.